Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial
Abstract Background Vitamin D (VD) may increase sirtuin 1 (SIRT1) and subsequently PPAR-γ coactivator 1α (PGC-1α) and irisin levels and these improvements may reduce insulin resistance (IR). The aim was to assess the effects of vitamin D supplementation on SIRT1, irisin, and IR in overweight/obese t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-02-01
|
| Series: | BMC Family Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12875-020-1096-3 |
| _version_ | 1818114204994895872 |
|---|---|
| author | Peivasteh Safarpour Milad Daneshi-Maskooni Mohammadreza Vafa Mitra Nourbakhsh Leila Janani Mohsen Maddah Fatemeh-Sadat Amiri Fereshteh Mohammadi Homa Sadeghi |
| author_facet | Peivasteh Safarpour Milad Daneshi-Maskooni Mohammadreza Vafa Mitra Nourbakhsh Leila Janani Mohsen Maddah Fatemeh-Sadat Amiri Fereshteh Mohammadi Homa Sadeghi |
| author_sort | Peivasteh Safarpour |
| collection | DOAJ |
| description | Abstract Background Vitamin D (VD) may increase sirtuin 1 (SIRT1) and subsequently PPAR-γ coactivator 1α (PGC-1α) and irisin levels and these improvements may reduce insulin resistance (IR). The aim was to assess the effects of vitamin D supplementation on SIRT1, irisin, and IR in overweight/obese type 2 diabetes (T2D) patients. Methods Ninety T2D males and females were recruited as a clinical trial study (mean of age and body mass index (BMI) of intervention and placebo groups were 50.05 ± 10.17 and 50.36 ± 10.2 yrs. and 31.37 ± 3.4 and 30.43 ± 3.2 kg/m2, respectively). The inclusion criteria were T2D, VD deficient, BMI > 25 kg/m2, and serum HbA1c < 8.5%. The exclusion criteria were using vitamin and mineral supplements, having any acute disease, recent modifying dose or type of drugs. The supplementation was 50,000 IU/week VD or placebo for 8 weeks. The demographic characteristics, anthropometrics, dietary intakes and physical activity status, sun exposure status, fasting blood sugar (FBS) and insulin, glycosylated hemoglobin (HbA1c), irisin, SIRT1, 25-hydroxy D3 (25(OH)VD), homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI) were determined. The significant P-value was ≤0.05. Results The increase of serum VD, SIRT1, and irisin in the intervention group was significant (p < 0.001). HbA1c was decreased significantly by 1%. The changes in the other glucose indices (FBS, insulin, and IR) were non-significant. Conclusions VD supplementation may improve T2D by decreasing HbA1c and increasing SIRT1 and irisin in VD deficient T2D patients. Further trials are suggested. Trial registration Iranian Registry of Clinical Trials, IRCT201604202365N11. Registered 21/08/2016, http://en.irct.ir/trial/2019 . |
| first_indexed | 2024-12-11T03:47:01Z |
| format | Article |
| id | doaj.art-fb723b76e9bd4b10bb3676f03bfd371c |
| institution | Directory Open Access Journal |
| issn | 1471-2296 |
| language | English |
| last_indexed | 2024-12-11T03:47:01Z |
| publishDate | 2020-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Family Practice |
| spelling | doaj.art-fb723b76e9bd4b10bb3676f03bfd371c2022-12-22T01:22:01ZengBMCBMC Family Practice1471-22962020-02-0121111010.1186/s12875-020-1096-3Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trialPeivasteh Safarpour0Milad Daneshi-Maskooni1Mohammadreza Vafa2Mitra Nourbakhsh3Leila Janani4Mohsen Maddah5Fatemeh-Sadat Amiri6Fereshteh Mohammadi7Homa Sadeghi8Department of Nutrition, School of Public Health, Iran University of Medical SciencesDepartment of Nutrition, School of Medicine, Jiroft University of Medical SciencesDepartment of Nutrition, School of Public Health, Iran University of Medical SciencesDepartment of Biochemistry, School of Medicine, Iran University of Medical SciencesDepartment of Biostatistics, School of Public Health, Preventive Medicine and Public Health Research Center, Iran University of Medical SciencesDepartment of Medicine, School of Medicine, Guilan University of Medical SciencesDepartment of Nutrition, School of Public Health, Iran University of Medical SciencesDepartment of Medicine, School of Medicine, Guilan University of Medical SciencesDepartment of Epidemiology, University of Massachusetts LowellAbstract Background Vitamin D (VD) may increase sirtuin 1 (SIRT1) and subsequently PPAR-γ coactivator 1α (PGC-1α) and irisin levels and these improvements may reduce insulin resistance (IR). The aim was to assess the effects of vitamin D supplementation on SIRT1, irisin, and IR in overweight/obese type 2 diabetes (T2D) patients. Methods Ninety T2D males and females were recruited as a clinical trial study (mean of age and body mass index (BMI) of intervention and placebo groups were 50.05 ± 10.17 and 50.36 ± 10.2 yrs. and 31.37 ± 3.4 and 30.43 ± 3.2 kg/m2, respectively). The inclusion criteria were T2D, VD deficient, BMI > 25 kg/m2, and serum HbA1c < 8.5%. The exclusion criteria were using vitamin and mineral supplements, having any acute disease, recent modifying dose or type of drugs. The supplementation was 50,000 IU/week VD or placebo for 8 weeks. The demographic characteristics, anthropometrics, dietary intakes and physical activity status, sun exposure status, fasting blood sugar (FBS) and insulin, glycosylated hemoglobin (HbA1c), irisin, SIRT1, 25-hydroxy D3 (25(OH)VD), homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI) were determined. The significant P-value was ≤0.05. Results The increase of serum VD, SIRT1, and irisin in the intervention group was significant (p < 0.001). HbA1c was decreased significantly by 1%. The changes in the other glucose indices (FBS, insulin, and IR) were non-significant. Conclusions VD supplementation may improve T2D by decreasing HbA1c and increasing SIRT1 and irisin in VD deficient T2D patients. Further trials are suggested. Trial registration Iranian Registry of Clinical Trials, IRCT201604202365N11. Registered 21/08/2016, http://en.irct.ir/trial/2019 .https://doi.org/10.1186/s12875-020-1096-3Vitamin DSIRT1IrisinGlucose indices, type 2 diabetesOverweight/obesity |
| spellingShingle | Peivasteh Safarpour Milad Daneshi-Maskooni Mohammadreza Vafa Mitra Nourbakhsh Leila Janani Mohsen Maddah Fatemeh-Sadat Amiri Fereshteh Mohammadi Homa Sadeghi Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial BMC Family Practice Vitamin D SIRT1 Irisin Glucose indices, type 2 diabetes Overweight/obesity |
| title | Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial |
| title_full | Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial |
| title_fullStr | Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial |
| title_full_unstemmed | Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial |
| title_short | Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial |
| title_sort | vitamin d supplementation improves sirt1 irisin and glucose indices in overweight or obese type 2 diabetic patients a double blind randomized placebo controlled clinical trial |
| topic | Vitamin D SIRT1 Irisin Glucose indices, type 2 diabetes Overweight/obesity |
| url | https://doi.org/10.1186/s12875-020-1096-3 |
| work_keys_str_mv | AT peivastehsafarpour vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT miladdaneshimaskooni vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT mohammadrezavafa vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT mitranourbakhsh vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT leilajanani vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT mohsenmaddah vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT fatemehsadatamiri vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT fereshtehmohammadi vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial AT homasadeghi vitamindsupplementationimprovessirt1irisinandglucoseindicesinoverweightorobesetype2diabeticpatientsadoubleblindrandomizedplacebocontrolledclinicaltrial |